Stanford Cancer Institute

Recent papers from Stanford Cancer Institute

1. Tyrosine kinase inhibitors are associated with reduced AML transformation in systemic mastocytosis with myeloid neoplasmBlood · 2026
2. Tiled base editing screens uncover rare second-site mutations that rescue a misfolded disease protein2026
3. Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumorsFuture Oncology · 2026
4. A BromoTag-Based Toolkit for Rapid Modulation of Chemically Induced ProximityACS Chemical Biology · 2026
5. Enhanced cfDNA methylation profiling by detection and correction of jagged endsNature Methods · 2026
6. GLP-1 receptor agonists and adverse outcomes in patients with type 2 diabetes and chronic viral hepatitisClinical and Molecular Hepatology · 2026
7. Integrating Community Health Workers for Genetic Cancer Screening in Primary Care for Latina WomenHealth Promotion Practice · 2026
8. American Society of Hematology 2026 Guidelines for the Management of Myelofibrosis in AdultsBlood Advances · 2026
9. Delays in breast cancer presentation, diagnosis, and treatment in young womenCancer · 2026
10. Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurinLeukemia · 2026
11. Burnout Factors in NeurologyNeurology Clinical Practice · 2026
12. “We Cannot Talk as a Family”: Complexities of Survivorship Communication Among Hispanic/Latino Young Adult Survivors of Childhood Cancer, Parents, and CliniciansPediatric Blood & Cancer · 2026
13. Beyond Tumor Size, Toward Meaningful Patient Outcomes—Resisting RECISTJAMA Oncology · 2026
14. Urine cell-free RNA for bladder cancer detection and treatment response predictionNature Medicine · 2026
15. Cost drivers of cancer sequencing technologiesnpj Precision Oncology · 2026
16. Five-year results of short-course brentuximab vedotin combined with chemotherapy and radiation in early stage, unfavorable Hodgkin lymphomaHaematologica · 2026
17. Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025Cancer · 2026
18. Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding studyGynecologic Oncology · 2026
19. Redox activation of ATG5 licenses autophagy upon nutrient restriction2026
20. Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementationEClinicalMedicine · 2026